Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis

Sun, Margaret Man-Ger; Pope, Janet

doi:10.1016/j.berh.2023.101822

Cited by 2 publications

(1 citation statement)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 In addition, PMR and GCA share multiple risk factors and pathogenic abnormalities, including genetic predisposing factors. 5 Mendelian randomization (MR) is an epidemiological approach to investigate the causal association between exposures and outcomes by using genetic variants, such as single nucleotide polymorphisms (SNPs). 6 Because germline genotypes are randomly allocated at conception, MR studies can reduce potential bias from confounding and reverse causation in contrast to conventional epidemiological methods.…”

Section: Genetically Determined Iron Status Was Associated With Polym...mentioning

confidence: 99%

Genetically determined iron status was associated with polymyalgia rheumatica but not with giant cell arteritis: A Mendelian randomization analysis

Xiao

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Section: Genetically Determined Iron Status Was Associated With Polym...mentioning

confidence: 99%

Genetically determined iron status was associated with polymyalgia rheumatica but not with giant cell arteritis: A Mendelian randomization analysis

Xiao

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Prospective assessment of glucocorticoid toxicity in rheumatology practice: a focus on the glucocorticoid toxicity index

Bahap-Kara,

Sariyildiz,

Zengin

et al. 2024

Rheumatology

View full text Add to dashboard Cite

Objective The glucocorticoid toxicity index (GTI) is developed to measure glucocorticoid (GC)-related morbidity over time. This study aimed to assess GC-toxicity in patients at a rheumatology outpatient clinic by using the GTI and to identify the factors that interfere with the GTI. Methods This prospective study included patients with inflammatory arthritis (IA), connective tissue disease, and vasculitis who were newly prescribed GC-treatment (GC-naive) or have been still on GC-treatment for ≤2 years (GC-experienced). Patient demographics and disease characteristics, aggregate improvement score (GTI-AIS), cumulative worsening score (GTI-CWS), and cumulative GC-doses were recorded at baseline, 3rd month, and 6th month. Generalized estimating equations (GEE) were used to evaluate the GTI scores and associated factors including cumulative GC-doses. Results The study included 156 (48.7% GC-naive) patients with a mean age of 49.1 ± 17.1 years. More than half of the patients in both groups had a diagnosis of vasculitis. A higher cumulative GC-dose was found to be associated with higher GTI-scores in both groups (p< 0.001). In the GC-naive group, patients with vasculitis showed higher GTI-scores than IA patients (p< 0.001); there was also a significant increase in the GTI-CWS at the 6th month compared with the 3rd month. In the GC-experienced group, GTI-AIS and GTI-CWS were significantly different at 3rd and 6th month (p< 0.05). Conclusion It was shown that GTI scores were associated with cumulative GC-doses and vasculitis patients in the GC-naive patients had higher GTI scores than inflammatory arthritis. The GTI allows individualized assessment and management of adverse effects experienced by patients as a result of GC treatment.

show abstract

Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis

Cited by 2 publications

References 79 publications

Genetically determined iron status was associated with polymyalgia rheumatica but not with giant cell arteritis: A Mendelian randomization analysis

Genetically determined iron status was associated with polymyalgia rheumatica but not with giant cell arteritis: A Mendelian randomization analysis

Prospective assessment of glucocorticoid toxicity in rheumatology practice: a focus on the glucocorticoid toxicity index

Contact Info

Product

Resources

About